LCAT-GMAC
Familial LCAT Deficiency
Phase 1Completed (Type 1 regenerative medicine study)
Key Facts
Indication
Familial LCAT Deficiency
Phase
Phase 1
Status
Completed (Type 1 regenerative medicine study)
Company
About CellGenTech
Japanese biotech developing one-time ex-vivo gene therapies using genetically modified human adipocytes for rare genetic diseases.
View full company profile